Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × talazoparib × Endocrine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 22 Genitourinary 11 Gynecologic 8 Tumor-Agnostic 7 Other hematologic neoplasm 6 Thoracic 4 Gastrointestinal 4 Sarcoma 2 Other solid neoplasm 2 CNS 2 Plasma cell 1 NET 1 Myeloid 1 Lymphoid 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 34 Everolimus 29 Magnetic Resonance Spectroscopy 20 pembrolizumab 17 Temozolomide 16 gallium Ga 68 dotatate 14 Nivolumab 14 Cisplatin 14 lenvatinib 13 lanreotide 13 cabozantinib 13 3-Iodobenzylguanidine 13 Capecitabine 12 trametinib 11 dabrafenib 11 Bevacizumab 11 Surgical Procedures, Operative 10 Octreotide 10 Surveys and Questionnaires 9 Positron Emission Tomography Computed Tomography 9 Paclitaxel 9 Blood Specimen Collection 9 Ipilimumab 8 Carboplatin 8 177Lu-octreotide, DOTA(0)-Tyr(3)- 8 fluorodopa F 18 7 Sunitinib 7 Sorafenib 7 Somatostatin 7 Radiotherapy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡